Recent Updates — AMGN
Amgen Inc. has appointed David W. Gibbs as a director, effective immediately. Gibbs brings extensive leadership experience from his tenure as Chief Executive Officer and President of Yum! Brands, where he oversaw digital transformation and global expansion. He currently serves on the boards of Under Armour and PepsiCo. Upon joining Amgen's Board, Gibbs will serve on the Audit Committee and the Compensation and Management Development Committee. The appointment brings the total number of directors to 13, with 12 classified as independent. As a non-employee director, Gibbs receives standard compensation including an annual cash retainer and equity grants. Amgen discovers, develops, manufactures, and delivers innovative medicines to treat serious diseases.
Amgen Inc. reported second quarter 2026 financial results on August 4, 2026. Total revenues increased 10% to $10.1 billion, driven by a 9% rise in product sales. GAAP earnings per share rose 65% to $4.37, while non-GAAP EPS increased 4% to $6.29. The company generated $3.5 billion in free cash flow and declared a quarterly dividend of $2.52 per share, paid on June 5, 2026, representing a 6% increase from the prior year. Full-year 2026 guidance projects total revenues between $38.2 billion and $39.4 billion and non-GAAP EPS between $22.30 and $23.50. Amgen Inc. operates in the biotechnology industry, discovering, developing, manufacturing, and delivering innovative medicines to treat cancer, heart disease, inflammatory conditions, rare diseases, and obesity.
Amgen Inc. disclosed a material cybersecurity incident in July 2026 involving unauthorized access to data stored in third-party cloud environments. The company confirmed that proprietary data, patient protected health information (PHI), and other sensitive information were exfiltrated. Amgen activated its response plan, implemented containment measures, and engaged independent forensic experts. While the investigation remains ongoing, the company stated there is no impact on products, manufacturing operations, or financial reporting systems. The incident was deemed material due to the volume of files and sensitivity of the data, though it is not expected to materially affect financial condition or results of operations. Amgen Inc. operates in the biotechnology industry, developing and commercializing human therapeutics.
Amgen announced that CFO Peter H. Griffith will retire on August 31, 2026, and will be succeeded by Thomas Dittrich effective September 1, 2026. The transition involves a significant compensation package for Dittrich, including a CHF 1,070,000 base salary and one-time incentives such as a CHF 4,700,000 RSU grant and a CHF 4,000,000 cash bonus to offset foregone equity. This leadership succession is a key development for investors monitoring the company's financial management and strategic continuity.
Amgen Inc. has released its unaudited financial results for the first quarter of 2026. The filing outlines the company's non-GAAP reconciliation methodology, which excludes acquisition-related and restructuring costs to help investors better evaluate core operating performance.